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Abstract
Chronic lead exposure induces hypertension in humans and animals, affecting endothelial function. However, studies concern-
ing acute cardiovascular effects are lacking. We investigated the effects of acute administration of a high concentration of lead 
acetate (100 µΜ) on the pressor response to phenylephrine (PHE) in the tail vascular bed of male Wistar rats. Animals were 
anesthetized with sodium pentobarbital and heparinized. The tail artery was dissected and cannulated for drug infusion and 
mean perfusion pressure measurements. Endothelium and vascular smooth muscle relaxation were tested with acetylcholine (5 
µg/100 µL) and sodium nitroprusside (0.1 µg/100 µL), respectively, in arteries precontracted with 0.1 µM PHE. Concentration-
response curves to PHE (0.001-300 µg/100 µL) were constructed before and after perfusion for 1 h with 100 µΜ lead acetate. 
In the presence of endothelium (E+), lead acetate increased maximal response (Emax) (control: 364.4 ± 36, Pb2+: 480.0 ± 27 
mmHg; P < 0.05) and the sensitivity (pD2; control: 1.98 ± 0.07, 2.38 ± 0.14 log mM) to PHE. In the absence of endothelium (E-) 
lead had no effect but increased baseline perfusion pressure (E+: 79.5 ± 2.4, E-: 118 ± 2.2 mmHg; P < 0.05). To investigate the 
underlying mechanisms, this protocol was repeated after treatment with 100 µM L-NAME, 10 µM indomethacin and 1 µM tempol 
in the presence of lead. Lead actions on Emax and pD2 were abolished in the presence of indomethacin, and partially abolished 
with L-NAME and tempol. Results suggest that acute lead administration affects the endothelium, releasing cyclooxygenase-
derived vasoconstrictors and involving reactive oxygen species.
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Environmental exposure to pollutant metals, including 
lead, contributes to cardiovascular disease (1). Moreover, 
this metal is recognized as a common environmental and 
occupational health hazard (2). Lead is an important toxic 
agent that can exert adverse effects in humans given suf-
ficient exposure and/or accumulation in the body (3). Ex-
perimental studies in animals and epidemiological reports 
suggest a close relationship between lead exposure and 
hypertension (4,5).
Lead is one of the metals most extensively used in the 
industrial sector in several countries including Brazil, a 
fact that contributes to its wide environmental distribution. 
Therefore, usually all humans have lead in their organism 
as a result of exposure to exogenous sources (6). Some 
workers are exposed to high levels of lead in their activities. 
This exposure occurs during the manufacture of ammuni-
tion, batteries, sheet lead, solder, ceramic glazes, caulking, 
some brass and bronze plumbing, circuit boards, military 
equipment, some surgical equipment, and some medicines 
(herbal remedies from China, India) (6). Barbosa Jr. et al. 
(7), studying 62 lead-exposed subjects, demonstrated a 
positive correlation between the increased inhibition of 
nitric oxide (NO) with increasing blood lead or plasma lead 
concentrations. These investigators suggested a significant 
inhibitory effect of lead on NO and provided clinical evidence 
for a mechanism involving the association between lead 
exposure and increased cardiovascular risk. 
Previous reports have suggested that lead acts at 
multiple sites within the cardiovascular system. Addition-
ally, chronic and acute lead poisoning causes cardiac and 
vascular damage with potentially lethal consequences (8,9). 
Lead also has other effects on the cardiovascular system, 
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including endothelial dysfunction (10) and inhibition of the 
sarcolemmal sodium potassium ATPase (11). These actions 
also include direct effects on the excitability and contractility 
of the heart (8,9), vascular actions on the compliance and 
contractility of smooth muscle (12-14), and tissue damage 
by free radicals (15). This metal also promotes reductions 
in vascular β-adrenoceptor density and cAMP levels, fac-
tors that contribute to increased blood pressure (16). In 
addition, harmful effects on other possible sites of action 
as within the central nervous system might occur affecting 
blood pressure regulation (17,18).
The actions of lead on the endothelium seem to involve 
the release of vasoactive factors, although the findings ob-
tained to date remain controversial. Previous findings have 
shown that lead exposure might increase (19) or decrease 
(20) plasma endothelin levels, as well as increase or de-
crease urine NO concentration or endothelial NO synthase 
(eNOS) overexpression (21). 
Although the chronic and acute effects of lead on liv-
ing animals are well known, there are comparatively few 
studies concerning the acute effects of lead on vascular 
reactivity. Therefore, the aim of the present study was to 
investigate the acute effects of continuous perfusion with a 
high concentration of lead acetate (100 µΜ) on the pressor 
reactivity of the perfused rat tail artery.
Material and Methods
Animals
Studies were performed on male Wistar rats (250-300 
g). All experiments were conducted in accordance with the 
guidelines for biomedical research as stated by the Brazilian 
Societies of Experimental Biology. The experimental proto-
col was approved by the Ethics Committee of the Institute of 
Biomedical Sciences, EMESCAM (Protocol #003/2007). All 
rats had free access to water and rat chow ad libitum. 
Isolated rat tail vascular bed preparation 
Isolated rat tail arteries were perfused as previously 
reported (22). Rats were first anesthetized with sodium 
pentobarbital (65 mg/kg, ip), and heparin (500 IU, ip) was 
administered 10 min later. At the base of the tail 2 cm of 
the tail artery were dissected free and cannulated with an 
intracath (Nipro 24G ¾, Brazil). The whole tail (average 
length of 18 to 20 cm) was then severed from the body, 
placed in a tissue bath and perfused at a constant flow of 2.5 
mL/min with a peristaltic pump (Milan, Brazil), with Tyrode 
solution (120 mM NaCl, 5.4 mM KCl, 1.2 mM MgCl2, 1.25 
mM CaCl2, 20 mM HEPES buffer, 11 mM glucose, and 3 
µM EDTA), bubbled with 100% O2, at 36 ± 0.5°C). 
The HEPES buffer was carefully chosen to prevent lead 
acetate precipitation. After a 45-min equilibration period, the 
experimental protocol was initiated. The mean perfusion 
pressure (MPP) was measured using a pressure transducer 
(TSD104A, BIOPAC Systems, Inc., USA), and data were 
recorded using an interface and software for computer data 
acquisition (model MP100A, BIOPAC Systems, Inc.). As a 
constant flow was maintained, changes in MPP represent 
changes in vascular resistance. 
Effects of the acute administration of lead on the  
actions of phenylephrine in the presence and  
absence of endothelium
After a 45-min stabilization period, endothelial integrity 
was evaluated using acetylcholine (Ach) administration 
(5 µg/100 µL) in the tail artery precontracted with 0.1 µM 
phenylephrine (PHE). Endothelial integrity was considered 
to be adequate when relaxation attained more than 50% of 
maximum contraction induced by a 0.1 µM PHE. Smooth 
muscle viability was tested using sodium nitroprusside (SNP: 
0.1 mg/mL) in the tail artery, which had been previously 
contracted with PHE. This test was performed before and 
after each complete experiment.
The vasoconstrictor response to the stimulation of an α1-
adrenoceptor agonist was evaluated by administering PHE 
(0.001-300 µg/100 µL) to preparations (N = 10) with intact 
endothelium (control group). After the first concentration-
response curve to PHE the preparations were perfused for 
1 h with a buffer solution containing 100 µΜ lead acetate 
and a second concentration-response curve of PHE was 
constructed in the presence of 100 µΜ lead acetate. To 
ensure that the effects were not dependent on time, an-
other group of rats was used under the same conditions 
in a time control experiment performed 1 h later, after iv 
administration of 0.9% saline. This lead concentration was 
selected because it is known to produce a clear negative 
inotropic effect and to reduce myosin ATPase activity in the 
rat myocardium (23). 
The same protocol was performed as described above 
in preparations following endothelium damage (E-: N = 10) 
induced by {3-[(3-cholamidopropyl) dimethylammonio]-1-
propane sulfonate} (CHAPS, 8 mg in 80 µL), as previously 
described (24). The absence of functional endothelium 
was confirmed by the inability of ACh (5 µg in 100 µL) to 
produce relaxation. The endothelium-independent vasodi-
lator response to SNP (0.1 mg/mL) was also determined. 
Concentration-response curves to PHE were constructed 
at 30 min after endothelial damage and repeated after 
perfusion with a solution containing 100 µΜ lead acetate 
for a period of 1 h (E- Pb2+, N = 10).
Time-control concentration-response curves to PHE 
(0.001-300 µg in 100 µL) were constructed before and after 
an infusion period of 1 h with Tyrode solution in preparations 
with (N = 10) and without endothelium (N = 10).
The role of prostanoids and nitric oxide in the  
effects of lead on the phenylephrine-induced  
pressure response 
To analyze the involvement of NO and prostanoids 
derived from cyclooxygenase (COX) activity in the effects 
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of lead acetate on the pressure responses to PHE, two 
protocols were performed. Preparations were perfused for 
1 h with 100 µM lead acetate in both situations: with the NO 
synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME 
100 µM, Pb2+ L-NAME, N = 13) and with indomethacin (10 
µM, Pb2+ indomethacin, N = 9), respectively. Basal NO 
release was evaluated by comparing the areas under the 
concentration-response curves for PHE, obtained in the 
absence and presence of L-NAME (25). The same protocol 
was also performed without lead acetate in the absence 
and in the presence of 10 µM indomethacin (N = 9) or 100 
µM L-NAME (N = 8). 
The role of free radicals in the effects of lead on the 
phenylephrine-induced pressure response
To investigate whether free radicals play a role in the 
effects of lead acetate on the pressure response to PHE, 
preparations were perfused for 1 h with 1 µM tempol 
(4-hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl), an agent 
that mimics superoxide dismutase (SOD), in the absence 
and in the presence of lead acetate. 
Drugs and reagents 
Lead acetate, PHE, L-NAME, indomethacin, tempol, 
ACh hydrochloride, SNP, CHAPS, HEPES, EDTA, and 
sodium pentobarbital were purchased from Sigma (USA); 
and heparin was purchased from Roche (Brazil). NaCl, 
KCl, MgCl2, CaCl2, and glucose were purchased from 
Merck (Germany).
The drugs were dissolved in distilled water and all 
solutions were freshly prepared before use and protected 
from light. Indomethacin was dissolved in 0.1 M Tris buf-
fer, pH 7.4. 
Data analysis
Results regarding perfusion pressure measurements are 
presented as changes in MPP by subtracting peak pressure 
from baseline pressure (ΔMPP, mmHg). The relaxation re-
sponses to ACh and SNP are reported as percent relaxation 
in preparations precontracted with 0.1 µM PHE.
For each PHE concentration-response curve, the 
maximum effect and the bolus dose (µg) that produced 
one-half Emax (-log EC50) were estimated using non-linear 
regression analyses (Graph Pad Prism Software, USA). 
The sensitivity of the agonist is reported as pD2 (-log EC50) 
and the maximum effect as maximal response (Emax). To 
compare the effects of different drugs on the response to 
PHE, results were reported as “differences of area under 
the concentration-response curves” (dAUC) in control and 
experimental situations. AUCs were calculated from the 
individual dose-response curves and the differences were 
reported as a percent of AUC (%dAUC) of the correspond-
ing control situation (26). 
Data are reported as means ± SEM and were analyzed 
by the Student t-test (paired or unpaired) and by one-way 
analysis of variance (ANOVA). When ANOVA showed a 
significant effect of treatment, the Tukey post hoc test was 
used to compare means. A P value <0.05 was considered 
to be significant.
Results
Effects of the acute administration of lead on the  
actions of phenylephrine in the presence and  
absence of endothelium
To evaluate the interference of the duration of the experi-
ments with the stability of the preparations, concentration-
response curves to PHE were constructed before and after 1 
h of continuous perfusion with Tyrode solution. This protocol 
showed that the duration of the experiments did not interfere 
with the Emax (before: 522 ± 19.6, after: 506 ± 13.2 mmHg) 
or the pD2 (before: 1.6 ± 0.04, after: 1.7 ± 0.03 log mM). 
On the other hand, 1 h of perfusion with lead acetate (100 
µΜ) increased Emax and pD2 (Figure 1A). 
Figure 1B demonstrates that, in the absence of en-
dothelium, lead acetate increased the baseline perfusion 
pressure (E+: 79.5 ± 2.4 vs E-: 118 ± 2.2 mmHg; P < 0.05, 
t-test) but did not change Emax or pD2 (Figure 1B). 
To investigate how acute lead acetate treatment af-
fected the endothelium or smooth muscle integrity, single 
doses of ACh, an endothelial-dependent vasodilator, and 
SNP, an endothelial-independent vasodilator, were used. 
Treatment with lead damaged the endothelium since the 
relaxation produced by ACh was significantly decreased 
(control: 60%; Pb2+: 20%; P < 0.05). The integrity of smooth 
muscle was preserved since SNP-induced vasorelaxation 
was unchanged (control: 81%; Pb2+: 91%).
Role of endothelial factors in the effects of lead 
L-NAME was used to investigate the putative role of NO 
in the effects of lead acetate on the pressor response to PHE. 
In control groups, L-NAME produced the expected increase 
in Emax and pD2 (Figure 2A). However, after perfusion with 
lead acetate plus L-NAME, a significant increase in Emax 
was observed when compared with the separate effect of 
L-NAME on the untreated preparations (Figure 2B). 
When the COX pathway-derived prostanoids were in-
vestigated with the use of indomethacin, just a small increase 
of Emax to PHE was observed before lead administration 
(control: 427 ± 35 vs indomethacin: 528 ± 37 mmHg; P 
< 0.05). After lead plus indomethacin administration, the 
increased pressor response to PHE, previously observed 
after lead treatment alone, was abolished (Figure 2C). 
However, under indomethacin treatment, NO production 
was still present. Then, the next step in our study was 
to evaluate whether the inhibition of NO production by 
L-NAME could demonstrate the participation of another 
vasoconstrictor agent. For this, we performed a protocol 
using the association of the two drugs, i.e., L-NAME and 
indomethacin in the presence of lead acetate. After this 
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procedure, it was observed that the Pb2+ L-NAME/indo-
methacin treatment showed a leftward displacement of the 
concentration-response curve to PHE (Figure 2D); however, 
the effects of lead on the Emax to PHE were abolished. The 
magnitude of the response of these groups was evaluated 
using the areas under the curves (Figure 2E). This analysis 
suggested the involvement of a COX-derived vasoconstrictor 
in the effect of lead.
The role of free radicals on the effects of lead acetate 
We also investigated the role of free radicals in the effect 
of lead. Tempol, an SOD mimetic, was used to investigate 
whether free radicals play a role in the action of 100 µΜ 
lead acetate on the pressor responses to PHE. Tempol 
promoted a small increase in the sensitivity to PHE (Figure 
3B). Moreover, in the presence of tempol, the effects of 
lead acetate were partially abolished (Figure 3C). Figure 
3D shows the magnitude of these responses. 
Discussion
The main finding of the present study shows that acute 
exposure to 100 µΜ lead acetate increases the reactiv-
ity of the tail artery to PHE. This increased reactivity is 
endothelium-dependent, since the effects of lead were 
abolished in the absence of endothelium. Additionally, this 
study demonstrated that COX inhibition by indomethacin 
prevented vasoconstriction, suggesting that the increased 
reactivity of the tail artery depends on the participation of 
a COX-derived vasoconstrictor. Results also showed that 
the blockade of the superoxide anion by tempol partially 
prevented the effects of lead, suggesting the involvement 
of free radicals in the effects of this metal. 
It is well established that chronic lead exposure in-
duces the production or release of endothelin, a powerful 
vasoconstrictor (19), inhibits the production or release 
of a hyperpolarizing factor (26) and reduces the release 
or production of NO (21,27). The combination of these 
lead-induced effects might increase vascular tonus and 
consequently blood pressure. 
These effects appeared to be related to an imbalance 
of endothelial-derived vasoconstrictor and vasodilator 
compounds (19). In addition, other investigators have 
demonstrated that chronic exposure to moderate levels 
of lead increases blood pressure (14,28), probably due to 
an increased vascular reactivity to α-adrenergic agonists. 
Previous studies have shown that chronic administration of 
this metal can act directly on vascular smooth muscle (29), 
also increasing the pressor response to norepinephrine in 
isolated arteries (20). In addition, Heydari et al. (30) reported 
that lead was able to increase Emax and pD2 in the pres-
ence of PHE in thoracic aortic rings of rats treated with lead 
for 8 to 12 weeks. Furthermore, it is known that this metal 
increases vascular responses to endogenous compounds 
such as norepinephrine (14) and enhances sympathetic 
activity, modifying the baroreflex sensitivity and inducing 
alterations in the signal transduction system present in cell 
membranes, such as cAMP, Ca2+ and NO (31).
To further understand the vasoconstrictor effect promoted 
by lead acetate and its capacity to harm the vascular en-
dothelium and the smooth muscle cells we investigated the 
actions of lead on the vascular reactivity of the tail artery.
Figure 1. Changes in mean perfusion pressure (∆MPP; mmHg) of the tail artery in response to increasing doses of 
phenylephrine in Wistar rats. A, With endothelium, before (control, open squares) and after (filled squares, Pb2+) infusion 
of 100 µΜ lead acetate for 1 h. B, Without endothelium before (open squares, E-) and after (filled squares, Pb2+) infusion 
of 100 µΜ lead acetate for 1 h. Data are reported as means ± SEM. *P < 0.05 for maximal response (Emax) and sensitivity 
(pD2): Pb2+ vs control (paired t-test). 
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Figure 2. Changes in mean perfusion pressure (∆MPP; mmHg) in response to increasing doses of phenylephrine in the 
tail artery of Wistar rats. A, Before (open squares, control) and after (filled triangles, L-NAME) perfusion with L-NAME. B, 
Effect of lead acetate in the absence (filled squares, Pb2+) and in the presence of L-NAME (open squares, Pb2+ L-NAME). 
C, Effect of lead acetate in the absence (filled squares, Pb2+) and in the presence of indomethacin (open squares, Pb2+ 
indomethacin). D, Effect of lead acetate in the absence (filled squares, Pb2+) and in the presence of L-NAME and indo-
methacin (open squares, Pb2+ L-NAME/indomethacin). E, Difference of areas under the concentration-response curves 
(dAUC) to phenylephrine for the following groups: Pb2+ vs control, L-NAME vs control, and Pb2+ L-NAME/indomethacin 
vs Pb2+. Data are reported as means ± SEM. *P < 0.05 for maximal response (Emax) and sensitivity (pD2): L-NAME vs 
control (paired t-test). *P < 0.05 for Emax: Pb2+ L-NAME vs Pb2+; Pb2+ L-NAME/indomethacin vs Pb2+ (unpaired t-test). 
Panel E, *P < 0.05 vs Pb2+ L-NAME (one-way ANOVA). 
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Our findings showed that the action of lead in the tail 
artery with intact endothelium increased the vasoconstrictor 
response to PHE, the maximal response (Emax) and the sen-
sitivity (pD2). These actions were endothelium-dependent, 
since lead effects were abolished after endothelium removal. 
Considering that a significant impairment of endothelial 
function was suggested, lead could be inhibiting the release 
of endothelium-derived vasodilators or stimulating the re-
lease of endothelial vasoconstrictors. Our findings seem to 
corroborate those of Marques et al. (32), as they reported 
that lead-induced hypertension damaged both endothelium-
dependent and -independent relaxation. This response 
was accompanied by increased eNOS protein expression 
and down-regulation of soluble guanylate cyclase (sGC). 
Marques et al. (32) also suggested that these responses 
seem to involve reactive oxygen species (ROS) acting on 
the relaxation mechanisms of NO/cyclic guanosine mono-
phosphate in the vascular wall. 
We observed a significant increase of the Emax promoted 
by lead acetate in the presence of L-NAME. However, L-
NAME was not able to completely abolish the response 
promoted by lead acetate. This result suggests that the 
Figure 3. Changes in mean perfusion pressure (∆MPP; mmHg) in response to increasing doses of phenylephrine 
in the tail artery of Wistar rats. A, Before (control, open squares) and after (Pb2+, filled squares) infusion of 100 µΜ 
lead acetate for 1 h. B, Before (control, open squares) and after (filled triangles) infusion of tempol. C, Effect of lead 
acetate in the absence (Pb2+, open squares) and presence of Tempol (Pb2+ Tempol, filled squares). D, Difference of 
areas under the concentration-response curves (dAUC) to phenylephrine between: (A: Control vs Pb2+; B: Control 
vs Tempol; C: Pb2+ Tempol vs Pb2+). Data are reported as means ± SEM. *P < 0.05 for maximal response (Emax) 
and sensitivity (pD2): Pb2+ vs control; #P < 0.05 for Emax: Pb2+ vs Pb2+ Tempol; +P < 0.05 for %dAUC: Pb2+ vs Pb2+ 
Tempol and Tempol (one-way ANOVA).
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effects on the pressor response to PHE cannot be totally 
attributed to NO. To better clarify this issue, our next step 
was to evaluate the pathway of COX-derived prostanoids. 
For this, preparations were treated with indomethacin, a 
COX inhibitor. We observed that the lead-induced vaso-
constrictor effects on the tail arterial bed were abolished 
by indomethacin. These results suggest that lead acetate 
might stimulate the release of COX-derived vasoconstric-
tor prostanoids. Although suggesting the production of a 
vasoconstrictor prostanoid, our findings did not enable us to 
distinguish which compound caused this. However, Courtois 
et al. (33) found an increase in the expression of COX-2 
protein in aortic rings perfused with lead and suggested 
that this response was associated with a deregulation of 
the β1-sGC subunit and an increased production of ROS 
as the vasoconstrictor mechanism.
Given that NO production was still present after inhibi-
tion by indomethacin because of the intact endothelium, the 
production of another endothelium-derived vasoconstrictor 
had to be taken into account. To better clarify this issue we 
also carried out a protocol associating two drugs, L-NAME 
and indomethacin, in the presence of lead. In this protocol, 
we observed a leftward displacement of the concentration-
response curve to PHE, which confirms that the effects of 
lead on the vascular tail bed are probably mediated by the 
release of a COX-derived vasoconstrictor plus another 
constrictor component.
There is growing evidence that the chronic effects of 
lead are also associated with oxidative stress (15,19,21). 
In contrast, previous studies have shown that ROS up-
regulates the expression of COX-2 isoforms, which is 
primarily responsible for the synthesis of prostaglandins 
involved in pathological processes, including hypertension 
(34). Therefore, the ability of lead acetate to generate ROS, 
specifically the superoxide anion (O2•- ), was evaluated. 
For this, the preparations were perfused with tempol. This 
treatment partially abolished the actions of lead acetate 
on the pressor response to phenylephrine, suggesting that 
acute treatment with lead probably involved the pathway 
of O2•-  production and/or liberation. Our findings show-
ing that COX is also involved reinforce the importance of 
ROS-induced generation by lead. However, this response 
does not rule out the possibility that the chronic action of 
this metal can induce the production of other kinds of free 
radicals, such as the radical hydroxyl (OH• -) and hydrogen 
peroxide (H2O2), as previously suggested (35,36). 
It is important to emphasize that the present findings 
reinforce the biological significance of lead as an environ-
mental contaminant that damages the human organism, 
producing harmful effects on the cardiovascular system. 
Although significant progress has occurred regarding 
environmental contamination, there are still serious prob-
lems produced by heavy metals. The positive correlation 
between the concentration of plasma lead and hyperten-
sion (37,38), one of the most prominent cardiovascular 
problems in many countries, and the increase in all causes 
of lead-related deaths, including circulatory and cancer 
mortality (39) reinforce the biological significance of lead 
as an important hazard. 
The results obtained thus far might be interpreted 
considering two limitations. The first limitation regards the 
lead concentration we used in this study, which is clearly 
toxic and far above safety values for human beings. We 
used a high lead concentration to begin to understand its 
effects. In the future, we will use smaller concentrations. 
The second limitation is that it is not possible to compare 
the present results with those for other vascular beds such 
as resistance vessels or the greater conductance vessels 
such as the aorta. However, the results of the present study 
provide guidance for further studies using much lower lead 
concentrations to better elucidate the cardiovascular effects 
of the metal.
In conclusion, the present study raises the possibility 
of a new mechanism of action of lead, i.e., an endothelial 
COX-derived vasoconstrictor mechanism, reinforcing the 
importance of ROS-induced generation by lead. 
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